Trial · NCT02546375
Results by group27
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 27
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Cumulative Complete Haematological Response (CHR) | Bosutinib | 93 | percentage of participants | ||
| Percentage of Participants With Cumulative Partial Haematological Response (PHR) | Bosutinib | 94 | percentage of participants | ||
| Percentage of Participants With Cumulative Complete Cytogenetic Response (CCyR) | Bosutinib | 67 | percentage of participants | ||
| Percentage of Participants With Cumulative Minor Cytogenetic Response (MCyR) | Bosutinib | 77 | percentage of participants | ||
| Percentage of Participants With Cumulative Minimal Cytogenetic Response (mCyR) | Bosutinib | 80 | percentage of participants | ||
| Percentage of Participants With Cumulative Partial Cytogenetic Response (PCyR) | Bosutinib | 77 | percentage of participants | ||
| Percentage of Participants With Cumulative Complete Molecular Response 4.0 (MR4.0) | Bosutinib | 33 | percentage of participants | ||
| Percentage of Participants With Cumulative Complete Molecular Response 4.5 (MR4.5) | Bosutinib | 27 | percentage of participants | ||
| Percentage of Participants With Cumulative Major Molecular Response (MMR)/Molecular Response 3.0 (MR3.0) | Bosutinib | 55 | percentage of participants | ||
| Percentage of Participants With Treatment Related Adverse Events (AEs) | Bosutinib | 94 | percentage of participants | ||
| Percentage of Participants With Treatment Related Adverse Events (AEs) Greater Than or Equal to Grade 3 | Bosutinib | 21 | percentage of participants | ||
| Progression-free Survival (PFS) | Bosutinib | NA | 95% Confidence Interval NA to NA | years | |
| Overall Survival (OS) | Bosutinib | NA | 95% Confidence Interval NA to NA | years | |
| Percentage of Participants With Disease Progression | Bosutinib | 1 year | 3 | percentage of participants | |
| Percentage of Participants With Disease Progression | Bosutinib | 2 year | 3 | percentage of participants | |
| Percentage of Participants With Disease Progression | Bosutinib | 3 year | 0 | percentage of participants | |
| Percentage of Participants With Permanent Discontinuation From Bosutinib Therapy | Bosutinib | Adverse event | 14 | percentage of participants | |
| Percentage of Participants With Permanent Discontinuation From Bosutinib Therapy | Bosutinib | Loss of response | 5 | percentage of participants | |
| Percentage of Participants With Permanent Discontinuation From Bosutinib Therapy | Bosutinib | Treatment failure | 11 | percentage of participants | |
| Percentage of Participants With Permanent Discontinuation From Bosutinib Therapy | Bosutinib | Participant request | 2 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02546375/results